Supplemental New Drug Application submitted for Zoryve (roflumilast) cream 0.3% to expand indication for treatment of plaque psoriasis in children ages 2 to 5 – Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA to expand the indication of Zoryve (roflumilast) ) cream 0.3% for the… read more.